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Heart failure (HF) is a leading cause of morbidity and mortality worldwide, with a 2-year mortality rate ap-
proaching 50% in patients with New York Heart Association 
(NYHA) class III and IV symptoms.1,2 Sympathetic nervous 
system (SNS) hyperactivity is a salient characteristic of HF.3–5 
Although it represents an early compensatory response aimed 
at enhancing cardiac contractility, sustained SNS activation 
exerts detrimental effects on the failing heart in the long term,3–
5
 and it is correlated with increased mortality in HF patients.4 
Consistently, β-adrenergic receptor (βAR) blockers have been 
shown to improve quality of life and to reduce rehospitalization 
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Rationale: Sympathetic nervous system hyperactivity is associated with poor prognosis in patients with heart failure 
(HF), yet routine assessment of sympathetic nervous system activation is not recommended for clinical practice. 
Myocardial G protein-coupled receptor kinase-2 (GRK2) is upregulated in HF patients, causing dysfunctional 
β-adrenergic receptor signaling. Importantly, myocardial GRK2 levels correlate with levels found in peripheral 
lymphocytes of HF patients.
Objective: The independent prognostic value of blood GRK2 measurements in HF patients has never been 
investigated; thus, the purpose of this study was to evaluate whether lymphocyte GRK2 levels predict clinical 
outcome in HF patients.
Methods and Results: We prospectively studied 257 HF patients with mean left ventricular ejection fraction of 
31.4±8.5%. At the time of enrollment, plasma norepinephrine, serum NT-proBNP, and lymphocyte GRK2 levels, as 
well as clinical and instrumental variables were measured. The prognostic value of GRK2 to predict cardiovascular 
(CV) death and all-cause mortality was assessed using the Cox proportional hazard model including demographic, 
clinical, instrumental, and laboratory data. Over a mean follow-up period of 37.5±20.2 months (range, 3–60 
months), there were 102 CV deaths. Age, left ventricular ejection fraction, New York Heart Association class, 
chronic obstructive pulmonary disease, chronic kidney disease, N-terminal-pro brain natriuretic peptide, and 
lymphocyte GRK2 protein levels were independent predictors of CV mortality in HF patients. GRK2 levels showed 
an additional prognostic and clinical value over demographic and clinical variables. The independent prognostic 
value of lymphocyte GRK2 levels was also confirmed for all-cause mortality.
Conclusions: Lymphocyte GRK2 protein levels can independently predict prognosis in patients with HF. 
(Circ Res. 2016;118:1116-1124. DOI: 10.1161/CIRCRESAHA.115.308207.)
Key Words: beta-adrenergic receptors ■ G-protein-coupled receptor kinase 2 ■ heart failure  
■ natriuretic peptide, brain ■ prognosis
Original received December 18, 2015; revision received February 11, 2016; accepted February 16, 2016. In January 2016, the average time from 
submission to first decision for all original research papers submitted to Circulation Research was 14.92 days.
From the Division of Cardiology, Salvatore Maugeri Foundation, IRCCS, Scientific Institute of Telese Terme (BN), Italy (G.R., G.G., D.F.V., N.F.); 
Division of Geriatrics, Department of Translational Medical Sciences (G.R., G.P., G.D.F., V.P., A.C., D. Liccardo, K.K., G.G., M.L.D.’A., C.d.L., N.F., 
D. Leosco), Division of Cardiology, Department of Advanced Biomedical Sciences (P.P.F., B.T.), Federico II University of Naples, Naples, Italy; SDN 
Foundation IRCCS, Institute of Diagnostic and Nuclear Development, Naples, Italy (S.P.); and Department of Pharmacology, Center of Translational 
Medicine, Temple University, Philadelphia, PA (A.C., D. Liccardo, W.J.K.).
This manuscript was sent to Sumanth Prabhu, Consulting Editor, for review by expert referees, editorial decision, and final disposition.
The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/doi:10.1161/CIRCRESAHA. 
115.308207/-/DC1.
Correspondence to Walter J. Koch, PhD, Department of Pharmacology, Center for Translational Medicine, Temple University School of Medicine, 3500 
N Broad St, MERB 941, Philadelphia, PA 19140. E-mail walter.koch@temple.edu; or Dario Leosco, MD, PhD, Department of Translational Medical 
Sciences, University of Naples Federico II, Via S. Pansini, 5, 80131 Naples, Italy. E-mail dleosco@unina.it
Prognostic Value of Lymphocyte G Protein-Coupled 
Receptor Kinase-2 Protein Levels in Patients  
With Heart Failure
Giuseppe Rengo, Gennaro Pagano, Pasquale Perrone Filardi, Grazia Daniela Femminella,  
Valentina Parisi, Alessandro Cannavo, Daniela Liccardo, Klara Komici, Giuseppina Gambino,  
Maria Loreta D’Amico, Claudio de Lucia, Stefania Paolillo, Bruno Trimarco,  
Dino Franco Vitale, Nicola Ferrara, Walter J. Koch, Dario Leosco
In This Issue, see p 1041 
Editorial, see p 1049
 at U
niversit? degli Studi di N
apoli -FedericoII on A
ugust 29, 2016
http://circres.ahajournals.org/
D
ow
nloaded from
 
 at U
niversit? degli Studi di N
apoli -FedericoII on A
ugust 29, 2016
http://circres.ahajournals.org/
D
ow
nloaded from
 
 at U
niversit? degli Studi di N
apoli -FedericoII on A
ugust 29, 2016
http://circres.ahajournals.org/
D
ow
nloaded from
 
 at U
niversit? degli Studi di N
apoli -FedericoII on A
ugust 29, 2016
http://circres.ahajournals.org/
D
ow
nloaded from
 
 at U
niversit? degli Studi di N
apoli -FedericoII on A
ugust 29, 2016
http://circres.ahajournals.org/
D
ow
nloaded from
 
 at U
niversit? degli Studi di N
apoli -FedericoII on A
ugust 29, 2016
http://circres.ahajournals.org/
D
ow
nloaded from
 
 at U
niversit? degli Studi di N
apoli -FedericoII on A
ugust 29, 2016
http://circres.ahajournals.org/
D
ow
nloaded from
 
 at U
niversit? degli Studi di N
apoli -FedericoII on A
ugust 29, 2016
http://circres.ahajournals.org/
D
ow
nloaded from
 
 at U
niversit? degli Studi di N
apoli -FedericoII on A
ugust 29, 2016
http://circres.ahajournals.org/
D
ow
nloaded from
 
Rengo et al  GRK2 and Prognosis in Heart Failure  1117
and mortality in HF patients.6–8 Thus, measurement of SNS 
activity has been suggested to help assessment of prognosis 
and clinical management of HF patients.9–11 However, although 
SNS hyperactivity measured through plasma circulating nor-
epinephrine (NE) levels,12 cardiac or renal NE spillover,13 heart 
rate variability,14,15 and iodine-123-metaiodobenzylguanidine 
(123I-MIBG) myocardial scintigraphy10,16–18 has prognostic val-
ue in HF patients, none of these approaches is routinely used in 
clinical practice or recommended by guidelines.11,19
It has been repeatedly reported that HF-related SNS hyper-
activity is responsible for enhanced cardiac G protein-coupled 
receptor kinase-2 (GRK2) levels,20–22 that is critically involved 
in the processes of cardiac βAR downregulation/desensitization, 
which occurs in HF.23–25 GRK2 is a serine–threonine kinase that 
by phosphorylating agonist-bound G protein-coupled receptors, 
including βARs, leads to the recruitment of arrestins and attenu-
ates intracellular G protein-dependent signaling.21,22 We and others 
have reported that enhanced GRK2 activity plays a key role in the 
pathogenesis of HF.21,22 Moreover, preclinical studies have shown 
that GRK2 inhibition in HF results in improved cardiac function, 
reverse remodeling, restoration of HF-related βAR abnormalities, 
and attenuation of SNS activity and neurohormonal responses.26–31
Of interest for this study, GRK2 expression measured in 
peripheral lymphocytes of HF patients correlates directly with 
levels of this kinase in failing myocardium and reflects the loss 
of hemodynamic function, the disease severity, and the degree 
of left ventricular (LV) dysfunction.32–34 Additionally, GRK2 
is comparably and significantly reduced in both lymphocytes 
and myocardium of HF patients after LV unloading and exer-
cise training.35,36 However, the prognostic value of lymphocyte 
GRK2 levels has never been investigated. This study aims to 
assess the value of lymphocyte GRK2 to predict outcome in 
patients with systolic HF. Our results do indeed suggest that 
blood GRK2 offers advantages over existing biomarkers and 
provide valuable data to predict HF outcomes.
Methods
Study Design and Population
The study was conducted at the Department of Translational Medical 
Sciences of the University Federico II (Naples, Italy) and at Salvatore 
Maugeri Foundation, Scientific Institute of Telese Terme (Telese 
Terme, BN, Italy) and was approved by the Local Ethical Committee. 
All patients gave written informed consent. We prospectively en-
rolled 303 consecutive patients with HF between January 2007 and 
July 2010. Of these 303 subjects, 21 subjects had to be excluded 
because of poor quality of lymphocyte extracts and 25 patients be-
cause of lack of serum N-terminal pro-brain natriuretic peptide (NT-
proBNP) values, leaving a final study population of 257 patients. 
To be included in the study, patients needed to fulfill the following 
criteria: diagnosis of HF due to ischemic or nonischemic causes; 
LV ejection fraction (LVEF) ≤45%; clinical stability of symptoms 
for at least 1 month before inclusion; and guidelines-based optimal 
pharmacotherapy. Exclusion criteria were cardiac revascularization 
or acute myocardial infarction within 3 months before study entry, 
uncontrolled hypertension (>180 mm Hg systolic or >110 mm Hg 
diastolic on measurements made on at least 3 separate dates during 
the preceding 3 months), severe chronic kidney disease (glomerular 
filtration rate <30 mL/min), comorbidity conditions associated with 
lymphocyte activation (ie, cancer, severe chronic diseases, ongoing 
infection, and excessive alcohol intake), and a life expectancy of <1 
year, based on noncardiac reasons. At the time of enrollment, all sub-
jects underwent a complete clinical examination (including NYHA 
functional class assessment and echocardiography) and blood draw 
for serum N-terminal-pro brain natriuretic peptide (NT-proBNP), 
lymphocyte GRK2, and plasma NE levels. Demographic data includ-
ing age, sex, HF medications, cardiovascular (CV) risk factors, and 
presence of comorbidities were also collected.
NT-proBNP Measurements
Level of NT-proBNP was determined by chemoluminescence 
(Elecsys 2010, Roche). The analytic range of the NT-proBNP assay 
extends from 1 to 25 000 pg/mL.37
Lymphocyte GRK2 Immunoblotting
Blood samples were collected from all patients in ethylenediamine-
tetraacetic acid tubes. Lymphocytes were isolated by ficoll gradient 
using HISTOPAQUE-1077 (Sigma), frozen, and stored at −80°C until 
the day of the assay. Immunodetection of GRK2 was performed us-
ing detergent-solubilized lymphocyte extracts after immunoprecipita-
tion (IP) as previously described.32 IPs were done using a monoclonal 
anti-GRK2/3 antibody (C5/1, Upstate) followed by Western blotting 
with a GRK2 polyclonal antibody (C-20, Santa Cruz Biotechnology). 
All IPs were done in protein lysates of the same quantity (ie, same 
starting amount in micrograms of protein, 1000 μg). As previous-
ly reported,32 post-IP lysates have been blotted for residual GRK2 
amounts, and typically none has been found demonstrating the quan-
titative nature of these experiments. Each IP was performed in dupli-
cate. To secure the linearity between optical density and GRK2 levels 
a standard curve was performed. The sample containing the protein 
to be quantified plus a set of standards were used. As standards we 
used 5 different dilutions of total lysates from lymphocytes of con-
trol patients that were used for GRK2-IPs. The dilution range was 
in an established order of magnitude (from 2000 to 200 μg). The 80 
kDa GRK2 protein was visualized using standard enhanced chemi-
luminescence (ECL Kit, Amersham). For an accurate quantification 
it was important that the light produced was in the linear range of 
the film. This was achieved by making several exposures of different 
lengths of time. Quantification of immunoreactive GRK2 was done 
by scanning the autoradiography film and using ImageQuant software 
(Molecular Dynamics). The concentration of the protein was quanti-
fied and read off a graph. To normalize data between different blots, 
a reference sample was run in all immunoblots and data from each 
individual patient were normalized to this sample. Intra- and interas-
say coefficient of variation were 5% and 15%, respectively.
Assessment of Outcomes and Follow-Up
The primary end point of the study was CV death, and all-cause 
mortality was a secondary end point. Causes of cardiac death were 
established after a review of hospital records, death certificates, and 
interviews with family members and family doctors. The patients ei-
ther visited the outpatient unit of the reference hospitals or were con-
tacted by telephone to determine their survival status. All causes of 
Nonstandard Abbreviations and Acronyms
βAR β-adrenergic receptor
CV cardiovascular
GRK2 G protein-coupled receptor kinase-2
HF heart failure
HR hazard ratio
IP immunoprecipitation
123I-MIBG Iodine-123-metaiodobenzylguanidine
LV left ventricular
LVEF left ventricular ejection fraction
NE norepinephrine
NT-proBNP N-terminal-pro brain natriuretic peptide
NYHA New York Heart Association
SD standard deviation
SNS sympathetic nervous system
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death were adjudicated by 2 physicians with disagreements resolved 
by referring to a third physician (Online Table I). Follow-up period 
was terminated at the end of the study period (on July 30, 2012) or in 
the case of death.
Statistical Analysis
Continuous variables are expressed as mean±standard deviation (SD) 
and compared by the use of Student’s t test (normally distributed) or as 
median±interquartile range value and compared by the use of Mann–
Whitney U test (not normally distributed), as appropriate. Normality 
of data distribution was evaluated using the Kolmogorov–Smirnov 
test. Not normally distributed continuous variables were natural log 
transformed (ln NE, ln GRK2, and ln NT-proBNP). Categorical vari-
ables are expressed as proportion and compared by use of χ2 test. 
Pearson correlation coefficient is calculated to assess correlation be-
tween data. The Cox proportional hazard analysis was used to identify 
the factors associated with CV and all-cause mortality. Using parsi-
monious criteria and taking into account the study sample size, 19 po-
tentially prognostic independent variables have been selected (at least 
10 patients were available for each prognostic factor tested). These 
factors were representative of several characteristics: basic demo-
graphic data (age and sex), presence of comorbidities (chronic kidney 
disease, defined as glomerular filtration rate ≤50 mL/min, diabetes 
mellitus, hypertension, and chronic obstructive pulmonary disease), 
resting systolic blood pressure and heart rate, presence of left bundle 
branch block, presence of low serum sodium (≤130 mEq/L), presence 
of low serum cholesterol (≤130 mg/dL), presence of hyperuricemia 
(≥ 6.7 mg/dL), medications (angiotensin-converting enzyme inhibi-
tor/angiotensin receptor blockers and β-blockers), functional classi-
fication by NYHA class, LVEF, circulating NE, serum NT-proBNP, 
and lymphocyte GRK2 protein levels. Only class NYHA II and III 
were present in the study population; therefore, the NYHA class was 
coded as a binary variable. Binary code was adopted for medications 
use and comorbidity presence.
The model-building strategy was centered on the multivariable 
fractional polynomials algorithm38,39 and was oriented to
1. select the factors significantly associated with the survival 
outcomes;
2. assess the functional form (linearity or nonlinearity) of the 
associations;
3. verify the proportional hazard assumption, using the multivari-
able fractional polynomial time algorithm40;
4. assess the calibration (goodness of fit) and the discrimination of 
the Cox models, the first by the Gronnesby and Borgan calibra-
tion test41 (comparing the observed with the estimated number 
of deaths in 5 risk score groups) and the second by both the 
global explained variation (R2) and the Harrel’s C index.
5. assess the potential incremental prognostic value of each fac-
tor by measuring the partial contribution of each variable to 
the global R2 of the linear combination (prognostic index) of 
the Cox model’s factors42 and by considering the hazard ratios 
(HR) relative to clinically meaningful factor’s variations;
6. evaluate the consistency (stability) and hence the internal valid-
ity of the results obtained, using the bootstrap technique43;
7. have an estimation of the potential additive clinical value of 
the GRK2 levels over the established factors by both the Net 
Reclassification Improvement and comparing the clinical net 
benefit curves obtained with decision curve analysis44 (see 
Model Building Strategy on Online Data Supplement).
The stability attained in each final model in which a given prog-
nostic factor was included as significant was measured by the number 
of times that the given variable was included as significant in a large 
(5000) number of bootstrap replications, applying the same multivari-
able fractional polynomials selection procedure (bootstrap inclusion 
frequency). The stability of the relationship between each variable 
and the survival was measured by the frequency (in the bootstrap sub-
set) of a significant linear versus nonlinear association.
To have a comprehensive view of the relative weight of each 
factor on the survival curve, the HR of the significant continuous 
variables included in the final Cox models were related to clinically 
meaningful variations (10 years period for age and 5% unit for LVEF) 
or to the interquartile range (75°–25° percentile difference) in case of 
NT-proBNP and lymphocyte GRK2 levels (because these factors lack 
a range with a definite clinical correlate).
Directly adjusted survival plots obtained averaging the Cox sur-
vival curves estimated using the covariate values of each subject 
are used to compare the survivals at specific factors’ values to the 
overall Kaplan–Meier.45 Data were analyzed by Stata version 13.0 
(StataCorp LP, College Station, Texas). Statistical significance was 
accepted at P≤0.05.
Results
Patient Characteristics
The final study group consisted of 257 patients (71.6% male) 
with mean age of 70.5±10.7, mean LVEF of 31.4±8.5%, and 
mean NT-proBNP of 1310±852 pg/dL. Only NYHA class II 
and III were present in the studied population (NYHA class II 
frequency of 18.3%). Demographic data of the overall study 
population and differences in the outcome groups are report-
ed in Table 1. To note, after patient stratification according 
to lymphocyte GRK2 median value (1.31 Densitometric Unit 
[DU]), β-blockers use and doses (low, medium, high) were 
equally distributed among patients with high and low lym-
phocyte GRK2 levels (Online Table II). Moreover, there were 
no differences in lymphocyte GRK2 levels between patients 
assuming different doses or patients not taking β-blockers 
(ANOVA P=0.46; Online Figure I).There were no differences 
in sex and medication usage between survivors and nonsurvi-
vors. Subjects who died were more likely to be older; diabetic 
and to have NYHA functional class III; worse kidney func-
tion; lower LVEF; and higher levels of NT-proBNP, NE, and 
lymphocyte GRK2 protein levels. Mean lymphocyte GRK2 
protein levels of HF patients was 1.42±0.71 DU, significantly 
higher (>2.5-fold; P≤0.01) compared with that of 37 healthy 
subjects (0.51±0.13 DU). Interestingly, lymphocyte GRK2 
showed a significant correlation with age, LVEF, NE, and NT-
proBNP levels. NT-proBNP presented a similar correlation 
profile (Table 2).
Analysis of Outcomes
Over a mean follow-up of 37.5±20.2 months (range: 3–60 
months) CV and all-cause deaths were 102 and 131, respec-
tively (final cumulative year mortality rate of 47.3±3.9% 
and 61.5±3.8%, with 60.3% and 49.0% censoring for CV 
and all-cause deaths, respectively). Specific causes of deaths 
are reported in Online Table I. Table 3 shows the rate of CV 
and all-cause deaths for quartiles of age, LVEF, lymphocyte 
GRK2, and NT-proBNP levels. Both CV and all-cause death 
rates show a significant constant increase along the quartiles 
of these 4 factors. Of note, the fourth GRK2 quartiles show a 
slight decrease in death rate compared with the third quartile. 
The more advanced age and the higher NT-proBNP values 
in the third respect to the fourth quartile of GRK2 could ac-
count for this observation (mean age of the 4 GRK2 quartiles 
= 67.0±9.6, 69.4±11.3, 73.0±11.0, and 72.4±9.8 respectively; 
mean NT-proBNP log of the 4 GRK2 quartiles= 6.50±0.7, 
6.86±0.8, 7.13±0.9, and 7.06±1.0, respectively). To overcome 
these confounding effects, we performed a multivariate Cox 
analysis and the resulting adjusted values are reported using 
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“*”in Table 3. Cox proportional hazard assumption was veri-
fied and hold for all variables in all final models. The stability 
of the results was documented by the high frequency of signif-
icant inclusion (above 90% for both NT-proBNP and GRK2) 
>5000 bootstrap study sample replications (Table 4), with the 
linear relationships being the most frequent functional form.
CV Death
Multivariate Cox proportional hazards regression analysis 
(Table 4 (cardiovascular death)) revealed that age, LVEF, 
NYHA class, chronic kidney disease, chronic obstructive pul-
monary disease, serum NT-proBNP, and lymphocyte GRK2 
protein levels were all independent and significant factors as-
sociated with CV mortality (full model). The model shows a 
global R2 of 0.48 and a Haller’s C=0.79±0.02, denoting that 
a good fraction of the outcome variability is explained and, 
hence, denoting an adequate discrimination. Other potential 
prognostic factors in HF, such as heart rate, systolic blood 
pressure, low serum cholesterol, low serum sodium, hyperuri-
cemia, and presence of left bundle branch block, did not show 
a significant association with CV death. However, low serum 
sodium presence was associated with a 69% greater hazard 
of CV death, just above the significant threshold (P=0.06). 
Good agreement between observed and Cox estimated death 
rate in 5 risk groups was acknowledged by a nonsignificant 
Gronnesby and Borgan calibration test (P=0.70). NYHA 
functional class III, NT-proBNP and blood GRK2 showed 
the greatest impact on cardiac mortality, as documented by 
their HR (>2.0). Interestingly, the partial R2 contributions was 
27.5%, 18.9%, and 8.7% for NT-proBNP, GRK2, and NYHA 
class, respectively, indicating that the 2 circulating biomark-
ers (NT-proBNP first) had the strongest contribution to the 
variation of the prognostic index (the linear combination of all 
factors in the Cox model). For the NYHA class, the apparent 
inconsistency between the HR and the R2 contribution could 
be explained by its skewed distribution (81.7% prevalence of 
the NYHA class III), considered that the actual distribution of 
a factor is one of the contributing determinants of the partial 
R2 other than its intrinsic weight (ie, HR).
Table 1. Characteristic of Patients in the Overall Study Population and in Patients Stratified in Survivors and Nonsurvivors
All (n=257) Survivors (n=126) Nonsurvivors (n=131) P
Age, yr 70.5±10.7 67.3±10.5 73.6±9.9 <0.0001
Sex, % male (n) 71.6 (184) 74.6 (94) 68.7 (90) 0.29
LVEF, % 31.4±8.5 35.5±7.4 27.5±7.6 <0.0001
NYHA class, % (n) II = 18.3 (47) II = 25.4 (32) II = 11.5 (15) 0.004
III = 81.7 (210) III = 74.6 (94) III = 88.5 (116)
SBP (mm Hg) 132.1±15.2 130.6±16.4 133.7±14.0 0.11
Resting HR (bpm) 73.5±9.6 73.1±10.1 73.9±9.2 0.48
LBBB, % (n) 14.0 (36) 13.5 (17) 14.5 (19) 0.92
Low serum sodium 
(<130 mEq/L), % (n)
15.9 (41) 15.8 (20) 16.0 (21) 0.972
Low serum cholesterol  
(<130 mg mg/dL), % (n)
8.5 (22) 8.7 (11) 8.3 (11) 0.7
Hyperuricemia  
(>9.5 mg/dL), % (n)
21.7 (56) 21.4 (27) 22.1 (29) 0.89
Comorbidity
  Hypertension, % (n) 76.3% (196) 77.0% (97) 75.6% (99) 0.88
  Diabetes mellitus, % (n) 45.1% (116) 38.9% (49) 51.1% (67) 0.03
  COPD, % (n) 29.2% (75) 27.0% (34) 31.3% (41) 0.49
  GFR <50 mL/mg, % (n) 35.8% (92) 25.4% (32) 45.8% (60) 0.001
Drugs
  ACE I/ARBs, % (n) 82.1% (211) 81.0% (102) 83.2% (109) 0.75
  β-Blockers, % (n) 51.8% (133) 54.8% (69) 48.9% (64) 0.38
Biochemical determinations
  Serum NT-proBNP,* pg/dL 1310±852 (1169/664–1767) 868±567 (809/425–1191) 1736±864 (1642/1028–2295) <0.0001
  Plasma norepinephrine,* pg/dL 606.7±246.4 (624/391–763) 551.7±227.3 (547/377–709) 659.5±253.3 (684/491–824) <0.0001
  Lymphocyte GRK2,* DU 1.42±0.71 (1.31/0.89–1.74) 1.17±0.62 (1.01/0.77–1.52) 1.66±0.71 (1.6/1.23–1.89) <0.0001
Normally distributed variables are expressed as mean±SD, binary data as percentage. P value refers to the survivors/nonsurvivors comparisons. ACE I indicates 
angiotensin-converting-enzyme inhibitor; ARBs, angiotensin receptor blockers; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; GRK2, G 
coupled-receptor kinase; HR, hazard ratio; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; 
NYHA, New York Heart Association; and SBP, systolic blood pressure.
*Not normally distributed variables are expressed as mean±SD (median/interquartile range value).
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The independent prognostic value of NT-proBNP and 
lymphocyte GRK2 on CV survival is graphically represented 
in Figures 1A and 1B. These curves were generated from the 
Cox parameters and showed the survival of the population 
at the same percentile value of the 2 markers compared with 
the overall Kaplan–Meier. The overall trend of these survival 
curves was comparable, depicting the similar impact of NT-
proBNP and GRK2 on cardiac survival.
Figure 2 shows the clinical net benefit profiles of the full 
model and of the 2 partial models obtained excluding alterna-
tively NT-proBNP or GRK2. The full model shows a clinical 
net benefit higher than the 2 partial models that, in turn, show 
practically overlapping net benefit profiles. Consistent results 
have been obtained with net reclassification improvement 
analysis as reported in Table 5.
All-Cause Death
Multivariate Cox model, shown in Table 2 (all-cause 
death), indicated that age, LVEF, chronic kidney disease, 
chronic obstructive pulmonary disease, serum NT-proBNP, 
and lymphocyte GRK2 protein levels were significantly 
associated with all-cause mortality, showing a global R2 
of 0.45, a Haller’s C=0.77±0.02 and a good calibration 
(nonsignificant Gronnesby and Borgan calibration test, 
P=0.98). Differently from cardiac mortality, NYHA class 
did not result an independent predictor of all-cause mor-
tality. As for CV mortality, heart rate, systolic blood pres-
sure, low serum cholesterol, hyperuricemia, and presence 
of left bundle branch block did not show a significant asso-
ciation with all-cause death. Similar to the results obtained 
for cardiac death, NT-proBNP and GRK2 were the stron-
gest factors with an equivalent impact on survival (HR, 2.1 
and 1.94 and partial R2 contributions, 29.6% and 21.7%, 
respectively).
Discussion
The findings of this study demonstrate, for the first time, that 
peripheral lymphocyte levels of GRK2 can independently pre-
dict mortality in patients with HF. The prognostic power of 
GRK2 measurement seems incremental to that provided by 
clinical, functional, and biohumoral parameters commonly 
used for risk stratification of HF patients, with an impact on 
both cardiac and all-cause mortality similar to that exerted by 
the NT-proBNP in our studied population.
GRK2 Signaling in HF
Increased cardiac sympathetic activity is associated with pro-
gressive myocardial remodeling, decline in LV contractility, 
worsening symptoms, and increase mortality in patients with 
chronic HF.3,4 Thus, SNS hyperactivity has been clinically in-
vestigated with the aim to improve risk stratification, and, po-
tentially, management of HF patients.4,11 Importantly, increased 
NE concentration induces downregulation and desensitization 
of myocardial βARs via GRK activity, and cardiac GRK2 up-
regulation has been recognized as 1 of the major responsible 
mechanisms of catecholamine-dependent βAR dysregulation 
and HF progression.23–25 Notably, increased lymphocyte and 
cardiac GRK2 levels have been detected in HF patients with 
lower LVEF and more severe symptoms.32–35 Moreover, me-
chanical unloading of failing human hearts is associated with 
decreased peripheral and cardiac GRK2 levels.32–35 Despite 
this evidence, no clinical studies have assessed the prognostic 
power of peripheral GRK2 measurements although this infor-
mation would be relevant to establish the clinical value of this 
novel biomarker in HF.
Table 2. Correlation Matrix of Continuous Variables
Age LVEF Norepinephrine Lymphocyte GRK2 NT-proBNP Heart Rate SBP
Age 1
LVEF −0.21* 1
Norepinephrine 0.15* −0.05 1
Lymphocyte GRK2 0.22* −0.36* 0.16* 1
NT-proBNP 0.47* −0.37* 0.40* 0.27* 1
Heart rate 0.12* 0.01 −0.03 0.03 0.07 1
SBP 0.01 −0.03 −0.03 0.12 −0.01 0.06 1
GRK2 indicates G protein-coupled receptor kinase-2; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; 
and SBP, systolic blood pressure.
*Significant coefficient (P≤0.05).
Table 3. Cardiovascular and All-Cause Death Rate Stratified 
by Quartile of Age, LVEF, Lymphocyte GRK2, and NT-proBNP
Quartile (%)
PFirst Second Third Fourth
Cardiac death rate
  Age 20.6 (26.8*) 27.9 (39.9*) 39.7 (45.9*) 67.1 (54.2*) ≤0.0001
  LVEF 66.1 (50.9*) 59.5 (47.5*) 28.0 (42.7*) 23.9 (37.1*) ≤0.0001
  GRK2 15.9 (28.3*) 26.6 (39.9*) 59.1 (48.2*) 56.3 (58.0*) ≤0.0001
  NT-
proBNP
9.23 (20.7*) 23.3 (38.8*) 47.1 (47.7*) 78.1 (58.3*) ≤0.0001
All-cause death rate
  Age 30.2 (39.8*) 44.3 (52.2*) 52.4 (57.5*) 74.3 (64.4*) ≤0.0001
  LVEF 89.3 (65.4*) 62.2 (60.6*) 37.6 (53.6*) 32.4 (45.0*) ≤0.0001
  GRK2 23.8 (39.1*) 34.4 (52.0*) 75.8 (60.5*) 68.8 (69.9*) ≤0.0001
  NT-
proBNP
21.5 (32.4*) 36.8 (52.1*) 58.8 (60.6*) 85.9 (70.1*) ≤0.0001
GRK2 indicates G protein-coupled receptor kinase-2; LVEF, left ventricular 
ejection fraction; and NT-proBNP, N-terminal pro-brain natriuretic peptide.
*Cox-adjusted cumulative death rate at 60 months.
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GRK2 as a Marker of Prognosis in HF
In this study, lymphocyte GRK2 protein levels were indepen-
dently associated, at multivariate analysis, with CV mortality 
and all-cause mortality. Lower lymphocyte GRK2 levels iden-
tified patients at low-risk mortality. In particular, patients with 
lymphocyte GRK2 protein levels at 25th percentile showed 
a lower incidence rate of CV death and all-cause mortality 
compared with patients with lymphocyte GRK2 protein levels 
at 75th percentile (Figure 2B). Notably, the prognostic infor-
mation provided by GRK2 values proved to be additional and 
comparable with that obtained by the most common prognos-
tic parameters used for risk stratification of HF patients, ie, 
LVEF and NT-proBNP. Moreover, assessment of lymphocyte 
GRK2 might have a role in the clinical practice, as demon-
strated by the improvement of the clinical net benefit derived 
from its introduction in the decision curve analysis (Figure 2) 
and by net reclassification improvement analysis (Table 5). 
Even in this condition, NT-proBNP and GRK2 contribution 
resulted to be equivalent.
These findings are consistent with those reported in the 
AdreView Myocardial Imaging for Risk Evaluation in Heart 
Failure (ADMIRE-HF) trial10 that assessed the prognostic 
value of 123I-MIBG cardiac imaging for risk stratification of 
patients with severe systolic HF. In that study, enrolling 961 
patients with mean LVEF of 27.1%, patients with 123I-MIBG 
heart to mediastinum ratio below the median (<1.60), reflect-
ing impaired cardiac innervations, showed a 6.22-fold in-
crease in the occurrence of cardiac death, with a prognostic 
value additional to that of LVEF and NT-proBNP, as reported 
in this study.10 As 123I-MIBG ratio parallels the status of βAR 
density in patients with HF,23,46 altogether the findings from 
the ADMIRE trial and the current findings similarly indicate 
that indexes of cardiac adrenergic derangement provide in-
dependent prognostic information on top of commonly used 
prognostic parameters in HF patients. Therefore, GRK2 levels 
in white blood cells have the potential to add, over the cur-
rently available biomarkers, important information on cardiac 
βAR signaling and function, whose status is progressively 
impaired in HF patients with relevant pathophysiological 
consequences.
Of note, despite a significant albeit weak (R2=5.7%; 
P=0.001) correlation between lymphocyte GRK2 protein 
Table 4. Cox Proportional Hazard Models for Cardiac Death and All-Cause Mortality
Cardiovascular Death (Global R2= 0.48; Haller’s C=0.79±0.02) All-Cause Mortality (Global R2=0.45; Haller’s C=0.77±0.02)
Hazard  
Ratio P
Percent  
Fraction of  
Global R2 (%)
Bootstrap  
Inclusion  
Frequency (%)
Linearity 
Stability (%)
Hazard 
Ratio P
Percent  
Fraction of 
Global R2 (%)
Bootstrap  
Inclusion  
Frequency (%)
Linearity  
Stability 
(%)
Age (10 yr) 1.51* 0.001* 17.5* 78.6* 76.30* 1.41* 0.002* 15.9* 80.0* 82.00*
Sex 0.96 0.86 NA 13.5 NA 1.09 0.67 NA 7.3 NA
LVEF (5% units) 0.86* 0.03* 13.2* 62.2* 87.60* 0.83* 0.003* 19.3* 76.1* 91.30*
NYHA 2.45* 0.02* 8.7* 62.7* NA* 1.56 0.12 NA 40.2 NA
ln NT-proBNP (IQ units) 2.23* ≤0.0001* 27.5* 95.7* 97.7*† 2.05* ≤0.0001* 29.6* 96.2* 99.2*†
ln GRK2 (IQ units) 2.01* ≤0.0001* 18.9* 89.1* 85.8*† 1.94* ≤0.0001* 21.7* 98.1* 75.9*†
Norepinephrine 0.90 0.53 NA 53.5 NA 0.99 0.40 NA 26.4 NA
Systolic blood pressure 1.01 0.13 NA 29.4 NA 1.01 0.11 NA 46.5 NA
Resting heart rate 1 0.08 NA 4.3 NA 1.00 0.99 NA 3.0 NA
LBBB 0.89 0.67 NA 15.2 NA 0.80 0.68 NA 14.3 NA
Low serum sodium 1.69 0.06 NA 55.0 NA 1.41 0.39 NA 35.6 NA
Low serum cholesterol 1.41 0.32 NA 16.4 NA 1.12 0.94 NA 11.3 NA
Hyperuricemia 0.89 0.64 NA 19.3 NA 0.78 0.56 NA 20.1 NA
Comorbidity
  Diabetes mellitus 1.16 0.46 NA 24.3 NA 1.10 0.59 NA 24.5 NA
  Hypertension 0.87 0.60 NA 28.8 NA 0.86 0.48 NA 40.5 NA
  COPD 1.81* 0.008* 3.0* 73.7* NA* 1.94* 0.001* 4.8* 84.0* NA*
  CKD 1.86* 0.003* 11.4* 70.3* NA* 1.54* 0.02* 8.8* 60.7* NA*
Drugs
  ACE I/ARBs 1.61 0.14 NA 55.6 NA 1.15 0.56 NA 17.9 NA
  β-Blockers 0.87 0.55 NA 16.8 NA 0.97 0.88 NA 9.0 NA
ACE I indicates angiotensin-converting-enzyme inhibitor; ARBs, angiotensin receptor blockers; CKD, chronic kidney disease (glomerular filtration rate ≤50 mL/min); 
COPD, chronic obstructive pulmonary disease; GRK2, G protein-coupled receptor kinase-2; IQ, interquartile (25°–75° percentile); LBBB, left bundle branch block; LVEF, 
left ventricular ejection fraction; NA, not applicable; NT-proBNP, N-terminal pro-brain natriuretic peptide; and NYHA, New York Heart Association.
*Statistically significant factors.
†Linearity stability for NT-proBNP and GRK2 refers to the stability of the logarithm form of these factors.
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levels and circulating plasma NE concentrations, NE did 
not independently predict CV death or all-cause mortality at 
multivariate analysis. This result might have at least 2 plau-
sible explanations: (1) the low reproducibility and sensitivity 
of plasma NE values,47 whereas GRK2 protein levels, more 
closely reflecting sustained hyperactivation of βAR by cate-
cholamines, may represent a more stable surrogate of SNS hy-
peractivity than circulating NE concentration; (2) lymphocyte 
GRK2 exerts a relevant effect on the mortality that captures 
the NE association with outcome and actually fully overcomes 
its prognostic information.
Finally, in our study, variables with an established rele-
vant effect on survival, such as LVEF, age, NT-proBNP, and 
NYHA class, resulted to be associated with outcomes, along 
with lymphocyte GRK2 levels. Regarding the lack of signifi-
cance for factors, such as the presence of diabetes mellitus, 
β-blocker use, heart rate, systolic blood pressure, low serum 
cholesterol, hyperuricemia, and presence of left bundle branch 
block, we can only speculate that it might be ascribed to the 
capture of a weak effect by the different and more prognosis-
impacting factors present in the model.
Study Limitations
This study reports a 2 center experience in a relatively small 
group of patients and, therefore, deserves further confirma-
tion in a multicenter study enrolling larger number of patients, 
thus allowing an external validation of the present results both 
from a prognostic and clinical utility point of view. Our study 
population was at particularly high CV risk, cautioning to ex-
trapolation of the current findings to other categories of HF 
patients. Thus, our results are certainly preliminary and must 
be confirmed in less severe HF populations. In addition, the 
definitive clinical relevance of our findings can only be as-
sessed in future studies testing whether improvement of the 
sympathetic innervation apparatus evaluated through monitor-
ing of GRK2 levels is associated with changes in outcomes of 
HF patients.
We did not verify the relationship between lymphocyte 
GRK2 and other measures of SNS activity, such as heart rate 
variability and cardiac 123I-MIBG. Although this might represent 
a study limitation for a study addressing the predictive power of 
a new biomarker reflecting SNS activity in HF, it is important 
to underline that: (1) there is still debate about the value of low 
frequency power of heart rate variability as a valuable measure 
Figure 1. Cardiovascular death free survival curves at different percentiles (5°, 25°, 50° (median), 75°, and 95°) of ln NT-proBNP (A) 
and ln GRK2 (B). The curves were obtained from the full Cox model, fixing the ln NT-proBNP in A and the ln GRK2 in B at the specific 
percentile, and adjusting for the other covariates at the values observed in the study population (directly adjusted curves). In A, the 
adjusting covariates include also the ln GRK2, whereas in B, ln NT-proBNP was included. GRK2 indicates G coupled-receptor kinase; HR, 
hazard ratio; IQR, interquartile range (25°–75° percentile); KM, Kaplan–Meier; NT-proBNP, N-terminal-pro brain natriuretic peptide; and 
pct, percentile.
Figure 2. Decision curve analysis for 60 months cardiac 
survival. The treat none and treat all curves are compared with the 
net benefit curves of 3 Cox models: full model (continuous black 
line), partial model—no N-terminal-pro brain natriuretic peptide 
(NT-proBNP, continuous gray line), and partial model—no G 
coupled-receptor kinase (GRK2; dashed black line). The full model 
profile is higher than the 2 partial model profiles across the critical 
range of the survival threshold probabilities (40–70%). The 2 partial 
models profiles overlap across the threshold span. All 3 models 
show curves well above that of the treat none and treat all.
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of cardiac sympathetic tone48; (2) cardiac 123I-MIBG was not 
available for a key fraction of our study population because this 
study has been planned before the demonstration of the clinical 
usefulness of this cardiac imaging technique.
Conclusions
Measurement of GRK2 protein levels in circulating lympho-
cytes provides additional and independent prognostic infor-
mation on all-cause and CV mortality in HF patients, over and 
above commonly used prognostic markers. Of noted impor-
tance, GRK2, differently from other biomarkers, is strictly 
related to cardiac adrenergic receptor function, whose dys-
regulation is a key point of HF pathophysiology and is the 
target of the most relevant therapy in this syndrome. Future 
important steps have to assess the clinical value of GRK2 as 
a new HF biomarker and for its potential introduction in the 
clinical practice, such as validation of the present results in 
larger HF populations, assessment of potential specific advan-
tages offered by lymphocyte GRK2 in the clinical manage-
ment of HF patients with ad hoc planned studies, and, finally, 
development of a more high-throughput GRK2 quantification 
assay for future potential clinical use.
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What Is Known?
•	 Upregulation of G protein-coupled receptor kinase-2 (GRK2) in heart 
failure (HF) causes dysfunctional β-adrenergic receptor signaling.
•	 GRK2 protein levels in circulating lymphocytes of HF patients correlate 
with cardiac levels and are reduced in response to HF effective thera-
pies (ie, exercise training and left ventricular assist device therapy).
What New Information Does This Article Contribute?
•	 Levels of GRK2 protein in lymphocytes predict prognosis (all-cause and 
cardiovascular mortality) in patients with HF.
•	 Prognostic information provided by lymphocyte GRK2 is additional, 
independent and of comparable extent to commonly used prognostic 
markers in HF (ie, NT-proBNP and left ventricular ejection fraction).
HF-related sympathetic nervous system hyperactivity is responsible 
for enhanced cardiac GRK2 levels, which in turn causes dysfunc-
tional cardiac β-adrenergic receptor signaling. GRK2 expression in 
peripheral lymphocytes correlates with the levels of this kinase in 
failing myocardium, reflecting the loss of hemodynamic function and 
the extent of the disease severity. In a cohort of 257 HF patients, we 
demonstrate that peripheral lymphocyte levels of GRK2 is associated 
with all-cause and cardiovascular mortality. This prognostic value of 
blood GRK2 levels is additional and independent to other biomarkers 
currently used in the clinical practice, such as NT-proBNP and left 
ventricular ejection fraction. However, in addition, GRK2 levels reflect 
the status of cardiac β-adrenergic receptor dysfunction, which plays 
a crucial role in HF pathophysiology and progression. These findings 
pave the way for future investigations testing the clinical value of 
GRK2 in larger and different HF populations.
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SUPPLEMENTAL MATERIALS 
 
Supplemental Methods 
Model building strategy 
The assessment of the impact on the outcome (survival) of several potentially influential variables requires 
their simultaneous evaluation in a single model in order to explain di effect of each factor independently of 
the others. This avoid the misleading conclusion that multiple single factor (univariate) models may cause, 
even if these are a good starting point. Thus, a multivariate analysis was planned and a multivariable model-
building strategy was carried out for the present study. 
Aware that there is no consensus among researcher on the ‘best’ strategy to find a ‘good’ model, we chose a 
pragmatic approach as proposed by Royston and Sauerbrei (1). In accord with these Authors, “by ‘good’ we 
mean a model that is satisfactory from the subject-matter point of view, robust with respect to minor 
variation of the current data, predictive in new data,  parsimonious and useful beyond the dataset on which it 
was created “(chap. 1.1.1 page 1 of ref 1).  
The strategy used can be summarized as follow. 
1. The initial step involves, first, the selection of the criteria employed to choose the pool of variables 
among which the subsequent analysis had to identify the factors relevant to the outcome and, second,  the 
selection of the model class to be used, i.e., the Cox model, being the outcome of interest the survival time.  
Having in mind the main aim of our model (assess the effect of a new factor of interest, adjusting for some 
established factors in a multivariable model) we selected a pool of variables representing known factors 
affecting the outcome (1). Parsimonious selection criteria were used to avoid overfitting bias. The rule of “at 
least 10 observed events for each tested variable” (chap. 2.9.1 page 47 of ref 1) adopted at an early stage of 
the analysis was relaxed to “at least 10 observed subjects for each tested variable”. This allows the 
assessment of a wider spectrum of candidate factors in a framework with an acceptable balance between the 
number of observations and the size of the model tested. 
2. The multivariable analysis follow.  The first aim of the analysis is the selection of the ‘important’ 
factors that independently affect the outcome picking them out as a subset of the initial pool by means of a 
stepwise selection algorithm. The second aim is the clarification of the functional form (linearity or non-
linearity) of the continuous predictors since the linearity assumption “may prevent one from recognize a 
strong effect or lead one to mismodel the effect” (chap 1.2.1 pag.8 of ref 1). The Multivariable Fractional 
Polynomial (MFP) modelling algorithm developed by Sauerbrei and Royston (2) addresses these two key 
tasks in multivariable model building: elimination of ‘unimportant’ variables and selection of a ‘reasonable’ 
dose-response function for continuous variables (chap. 1.7.3 page 19 of ref 1). The MFP algorithm combines 
a backward variables elimination with a search for the best functional form (linear or not linear) of 
continuous variables (ref. 1, 2). 
3. The weight of each significant factor in the model is evaluated by both the hazard ratio and by the 
contribution to the global explained variation (R2). The partition of the global R2 is accomplished by the 
Shapley-Owen decomposition algorithm (3). The hazard ratio of continuous variables is related to clinically 
meaningful variation (e.g. 10 years period for age, 5% units for left ventricular ejection fraction).  For 
variables without a range of definite clinical meaning the hazard ratio relative to the interquartile range  (75°-
25° percentile difference) is employed. This allows comparison of the relative weight between factors and 
give a measure of the factor relevance on the studied population (e.g. NT-proBNP, GRK2, and 
norepinephrine).  The interquartile range was preferred over the standard deviation given the non normal 
distribution of the variables. 
4. Since the Cox model was adopted, it was mandatory to verify the proportionality assumption 
inherent with the basic formulation. To this end we used a modified version of the MFP (the MFPT) devoted 
to comprehensively explore the time-variable(s) interaction in order to check the assumption (chap. 11.1.1 
page 242-243 of ref 1). 
5. The next step involve the computation of model performance measures, i.e., calibration, 
discrimination ability and internal validity.  
a) The first is a goodness of fit assessment that we accomplished with the Gronnesby and Borgan 
calibration test (4). This test verifies the concordance between the observed survival (Kaplan Meier) and the 
survival estimated with the Cox model in five risk groups of the studied population. Five contiguous strata of 
the prognostic index (the linear combination of the factors with their Cox coefficients) identify the risk 
groups. Non-significant test indicates good calibration (4).  
b) The discrimination ability refers to how well the model can distinguish between patient outcomes. 
We used two indices to quantify it, first the Harrel’s C as a natural extension of the binary logistic C statistic 
(the area under the ROC curve), specifically we used a Harrel’s C version corrected for the censoring bias as 
suggested by Gonen and Heller (5). Second, we used a measure of the explained variance in the natural scale 
of the Cox model (R2) as proposed by Royston and Sauerbrei (6). 
c) Adhering to the suggestion expressed by Royston and Sauerbrei (chap 2.2 page 24 of ref 1) we 
measured the internal validity of the model by assessing the stability of the model characteristics with 
nonparametric bootstrap sampling (chap 8 page 183-186 of ref 1). Briefly, given the parameters of a model 
obtained applying the described model-building procedure,  the stability of each factor tested in the model is 
measured by the frequency that this factor is selected as ‘significant’ in a series of bootstrap replications of 
the dataset by applying the same procedure. Each bootstrapped dataset may be considered as a random 
replicate of the original dataset. 
External validity cannot be evaluated since it requires an independent dataset (i.e. an independent HF 
population) on which verify the model obtained in the studied population. Splitting the available dataset in 
‘test’ and ‘training’ groups is also not feasible since it would require a greater dataset dimension. 
Therefore, as we pointed out in the limitations, the external validity had to be deferred to future studies.  
6. The assessment of the clinical utility of a new marker is a mandatory step before its employment in 
the clinical practice and requires an ‘ad hoc’ study design oriented to the specific characteristics of the 
marker and of the clinical pathology involved. However, great interest has been raised by the possibility of 
gather measures of clinical utility from the same dataset used to assess the impact of a new biomarker. 
Several measures of usefulness have been suggested and gained popularity.  These include the Net 
Reclassification Improvement (NRI) (7), weighted NRI (wNRI) (8), Net Benefit (NB) (9) and Relative 
Utility (RU) (10). A study comparing the performance of all these indices (11) concluded that the three 
utility measures that take into account misclassification cost (wNRI, NB and RU) are preferable over the 
NRI and, “being a mathematical transformations of each other, lead to equivalent information”.  Notably, the 
Authors that first introduced the named indices jointly conducted this study.  The Authors concluded 
recommending the use and report of these decision-analytic measures for a range of risk thresholds, thus 
grounding the deduction over a meaningful range of risk.  
We, therefore, adopted the NB plots of different models over a wide risk range to enlighten the utility of the 
new biomarker.  
As regards the way to illustrate graphically the effect of the factor of interest on the outcome (survival), since 
the stratified Kaplan Meir graphs cannot take into account the presence of confounding, survival curves 
adjusted by influential covariate have to be employed. 
We adopted the directly adjusted survival curve method (12), namely, for each subject in the data set a 
survival curve is computed using the estimated Cox model. Each curve is obtained using the covariate values 
specific of each subject except for the factor of interest that is set to a given value for all curves. An average 
curve is then computed.  This curve represent an estimate of the Kaplan Meier survival curve that would be 
observed if all subjects in the study population had had the factor of interest at the chosen value. Actually, if 
the process is carried out using the values observed for each subject for all covariates (including the one of 
interest) the curve obtained indeed ‘is’ the overall Kaplan Meier. 
Thus a plot of ‘directly adjusted curves’ at the appropriate factor of interest values along with the standard 
overall Kaplan Meier will give graphical view of the strength of the effect of the factor of interest 
independent from confounding. 
STATA (v.13.0) was used to perform all analyses. 
  
Supplemental Table I. Adjudicated causes of death and rates of death by cause  
        
  N % of pts % of deaths 
All Cause Deaths 131 51.0%   
Cardiovascular deaths 102 39.7% 77.9% 
  Sudden 42 16.3% 32.1% 
  Worsening HF 26 10.1% 19.8% 
  Fatal Stroke 5 1.9% 3.8% 
Other Cardiovascular 29 11.3% 22.1% 
        
Non Cardiovascular  27 10.5% 20.6% 
  Infection 14 5.4% 10.7% 
  Malignancy 11 4.3% 8.4% 
  Other 2 0.8% 1.5% 
        
Unknown 2 0.8% 1.5% 
HF= heart failure; MI= myocardial infarction ; pts=patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table II. Beta blocker dose distribution in patients with lymphocyte GRK2 below and above 
the median value.  
Beta Blockers therapy dose 
  Low Medium High 
Pts below lymphocyte GRK2 median value      (≤ 
1.31 D.U.), % (n) 44.8% (30) 43.3% (29) 11.9% (8) 
Pts above lymphocyte GRK2 median value      (> 
1.30 D.U.), % (n) 50.0% (33) 39.4% (26) 10.6% (7) 
  p=0.833 
 
GRK2= G protein-coupled receptor kinase 2.Pts= patients 
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Supplemental Figure I. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lymphocyte GRK2 levels in patients not assuming beta-blocker therapy and in patients at low, medium and 
high doses of beta-blocker therapy. BBlocker= beta-blocker
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